LDK1229

CAS No. 1800285-55-5

LDK1229 ( LDK 1229 )

Catalog No. M12734 CAS No. 1800285-55-5

LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    LDK1229
  • Note
    Research use only, not for human use.
  • Brief Description
    LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.
  • Description
    LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM; exhibits 3-fold relative selectivity for the CB1 over CB2, exhibits efficacy comparable with SR141716A in antagonizing the basal G protein coupling activity of CB1; increases cell surface localization of CB1 and structurally distinct from the first-generation CB1 inverse agonists.
  • Synonyms
    LDK 1229
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    Cannabinoid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1800285-55-5
  • Formula Weight
    434.96
  • Molecular Formula
    C24H29ClF2N2O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Mahmoud MM, et al. Mol Pharmacol. 2015 Feb;87(2):197-206.
molnova catalog
related products
  • AM-1221

    A potent and selective agonist for the cannabinoid receptor CB1 with Ki of 0.28 nM, 180-fold selectivity over CB2.

  • CP-724714(b)

    CP-724714 is an effective and selective HER2/ErbB2 inhibitor (IC50: 10 nM), >640-fold selectivity against EGFR, Abl, InsR, PDGFR, IRG-1R, Src, VEGFR2, c-Met etc.

  • VCE-004.3

    VCE-004.3 (VCE004.3) is a novel semi-synthetic cannabidiol derivative behaving as a dual PPARγ/CB2 agonist and CB1 receptor modulator.